Overview

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The primary endpoint is to evaluate the progression-free survival (PFS).
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Cetuximab
Irinotecan